Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IVH4
UPID:
MMAA_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IVH4; B3KX40; Q495G7
Background:
The Methylmalonic aciduria type A protein, mitochondrial, is a pivotal enzyme in vitamin B12 metabolism. It functions as a GTPase, facilitating the transport and transformation of cobalamin into adenosylcobalamin within mitochondria. This protein also acts as a chaperone and protectase for the methylmalonyl-CoA mutase, playing a crucial role in preventing enzyme inactivation and promoting metabolic balance.
Therapeutic significance:
Given its central role in methylmalonate and cobalamin metabolism, mutations affecting this protein lead to Methylmalonic aciduria type cblA. Understanding the role of Methylmalonic aciduria type A protein could open doors to potential therapeutic strategies, offering hope for targeted treatments for affected individuals.